WASHINGTON, DC—In patients with right ventricular outflow tract (RVOT) conduit dysfunction, transcatheter pulmonary valve (TPV) replacement demonstrates high procedural success, excellent short-term ...
Excellent safety and tolerability product profile Potential for PL9643 to address multiple signs and symptoms of dry eye disease CRANBURY, N.J., Sept. 7, 2023 /PRNewswire/ -- Palatin Technologies, Inc ...
EINDHOVEN, Netherlands, Jan. 24, 2024 /PRNewswire/ -- Sirius Medical is proud to celebrate the enrollment of the first patient in the MELODY Study using the innovative Sirius Pintuition System by Prof ...
Palatin Technologies, Inc. PTN announced that it has initiated the pivotal phase III MELODY-1 study evaluating its melanocortin agonist, PL9643, for the treatment of patients with dry eye disease ...
Palatin Technologies, Inc., a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results